Research Progress on the Combination of ADC Drugs and Immunotherapy in Non-Small Cell Lung Cancer
Abstract
which has a poor prognosis. Molecularly targeted drugs and immune checkpoint inhibitors (ICIs) have become the mainstay of first-line treatment, but drug resistance significantly affects the durability of clinical responses. However, the combination of ADCs with ICIs may have
synergistic potential as ADCs not only mediate targeted tumor killing but also have immunomodulatory properties such as immunogenic cell
death and activation of dendritic cells. However, achieving durable remission, even after the current progress with targeted therapy, anti-angiogenic agents, ICIs and ADCs, is a huge challenge. The goal of this review is to provide an overview on the synergistic mechanisms acting in
ADC–immunotherapy combination approaches, recent clinical advances in first-line treatment, and safety management considerations to help
guide clinical practice and future investigations.
Keywords
Full Text:
PDFReferences
[1] Liu, Xinlin., Liu, Xinlin., Deng, Junwen., Deng, Junwen., Zhang, Renshuai.. The clinical development of antibody-drug conjugates for
non-small cell lung cancer therapy. Frontiers in immunology, 2023. Doi:10.3389/fimmu.2023.1335252
[2] Zhao, Chenyu., Zhang, Ruihan., Yang, Huazhe., Gao, Yiwei., Zou, Ying.. Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation. Biochemical pharmacology, 2024. Doi:10.1016/j.bcp.2024.116378
[3] Xu X, Yu T, Wang Z. Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy. Cancer Treat Rev. 2025;140:103012. doi:10.1016/j.ctrv.2025.103012
[4] Wang L, Du C, Jiang B, Chen L, Wang Z. Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune
microenvironment in lung cancer. Front Immunol. 2023;14:1256740. Published 2023 Oct 9. doi:10.3389/fimmu.2023.1256740
[5] He L, Sun Y, Ma B, et al. Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of in vivo CAR-T platforms. Front Immunol. 2026;17:1772428. Published 2026 Apr 21. doi:10.3389/
fimmu.2026.1772428
[6] Mountzios G, Saw SPL, Hendriks L, et al. Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart
delivery of chemotherapy to the target. Cancer Treat Rev. 2025;134:102902. doi:10.1016/j.ctrv.2025.102902
[7] Gomis, Gabriel., Berraondo, Pedro., Herrero, Claudia., Luri-Rey, Carlos., Melero, Ignacio.. Cross-priming underlies the efficacy of
antibody-drug conjugates and immunotherapy combinations. Trends in immunology, 2026. Doi:10.1016/j.it.2026.06.003
[8] Somme LB, Chouaid C, Moinard-Butot F, Barbe-Richaud JB, Greillier L, Schott R. Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers. BioDrugs. 2024;38(4):487-497.
doi:10.1007/s40259-024-00660-7
[9] Ismail, Ahmed., Desai, Aakash., Simon, George R., Boumber, Yanis.. Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell
Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions. Biomolecules, 2026. Doi:10.3390/biom16050677
[10] Trontzas IP, He M, Wurtz A, et al. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wildtype Non-Small Cell Lung Cancer. Clin Cancer Res. 2025;31(13):2767-2776. doi:10.1158/1078-0432.CCR-24-3347
[11] Deng S, Sun C, Liu D, et al. Antibody-drug conjugates: A new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer.
Pharmacol Res. 2026;223:108066. doi:10.1016/j.phrs.2025.108066
[12] Bylicki O, Tomasini P, Radj G, et al. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage
IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. Eur J Cancer. 2023;183:38-48. doi:10.1016/
j.ejca.2023.01.014
[13] Guo H, Xu Z, Li K, et al. Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer. Front Immunol.
2026;17:1787148. Published 2026 Feb 18. doi:10.3389/fimmu.2026.1787148
[14] Petrelli F, Dottorini L, D'Alessio A, et al. Interstitial lung disease in patients treated with antibody-drug conjugates: a review. Lung Cancer. Published online July 11, 2026. doi:10.1016/j.lungcan.2026.109532
[15] Guo XJ, Cai XT, Rong ZX, et al. Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation. BMC Med. 2023;21(1):6. Published 2023 Jan 5. doi:10.1186/
s12916-022-02713-6
[16] Wang, Jia-Feng., Jiang, Lei-Lei., Wang, Meng-Chuan., Li, Yang-Ling.. Targeted Therapy-Induced Interstitial Lung Disease in NSCLC:
Mechanisms, Clinical Signatures, and a Precision Medicine Roadmap. Drug design, development and therapy, 2026. Doi:10.2147/
DDDT.S600434
[17] Zhang Q, Duan J, Zhang Y, Yang L, Li D. Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable nonsmall cell lung cancer: a systematic review and network meta-analysis. Syst Rev. 2025;14(1):24. Published 2025 Jan 24. doi:10.1186/
s13643-025-02767-6
[18] Zhang M, Fan Y, Nie L, Wang G, Sun K, Cheng Y. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With
Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis. Chest.
2022;161(6):1675-1686. doi:10.1016/j.chest.2021.12.656
DOI: http://dx.doi.org/10.70711/frim.v4i9.10235
Refbacks
- There are currently no refbacks.
